Our 24/7 cancer helpline provides information and answers for people dealing with cancer. We can connect you with trained cancer information specialists who will answer questions about a cancer diagnosis and provide guidance and a compassionate ear.
Our highly trained specialists are available 24/7 via phone and on weekdays can assist through video calls and online chat. We connect patients, caregivers, and family members with essential services and resources at every step of their cancer journey. Ask us how you can get involved and support the fight against cancer. Some of the topics we can assist with include:
For medical questions, we encourage you to review our information with your doctor.
A risk factor is anything that affects your chance of getting a disease such as cancer. Different cancers have different risk factors. Some risk factors, like smoking, can be changed. Others, like a person’s age or family history, can’t be changed.
But having a risk factor, or even many, does not mean that you will get the disease. And some people who get the disease may not have any known risk factors.
Scientists have found that certain risk factors make a woman more likely to develop vaginal cancer. But many women with vaginal cancer don’t have any clear risk factors. And even if a woman with vaginal cancer has one or more risk factors, it’s impossible to know for sure how much that risk factor contributed to causing the cancer.
Squamous cell cancer of the vagina occurs mainly in older women. It can happen at any age, but few cases are found in women younger than 40. Almost half of cases occur in women who are 70 years old or older.
DES is a hormone drug that was used from 1940 and 1971 to prevent miscarriage. Women whose mothers took DES when pregnant with them develop clear-cell adenocarcinoma of the vagina or cervix more often than would normally be expected. There's about 1 case of this type of cancer in every 1,000 daughters of women who took DES during their pregnancy. This means that about 99.9% of DES daughters do not develop this cancer.
DES-related clear cell adenocarcinoma is more common in the vagina than the cervix. The risk appears to be greatest in those whose mothers took the drug during their first 16 weeks of pregnancy. Their average age when they are diagnosed is 19 years. Since the use of DES during pregnancy was stopped by the FDA in 1971, even the youngest DES daughters are older than 45 – past the age of highest risk. But a woman is not safe from a DES-related cancer at any age. Doctors don't know exactly how long women remain at risk.
DES daughters have an increased risk of developing clear cell carcinomas, but women don’t have to be exposed to DES for clear cell carcinoma to develop. In fact, women were diagnosed with this type of cancer before DES was invented.
You can learn more in DES Exposure: Questions and Answers.
Normally, the vagina is lined by flat cells called squamous cells. In about 40% of women who have already started having periods, the vagina may have one or more areas lined instead by glandular cells. These cells look like those found in the glands of the cervix, the lining of the body of the uterus (the endometrium), and the lining of the fallopian tubes. These areas of gland cells are called adenosis. This occurs in nearly all women who were exposed to DES during their mothers’ pregnancy. Having adenosis increases the risk of developing clear cell carcinoma, but this cancer is still very rare. The risk of clear cell carcinoma in a woman who has adenosis that's not related to DES is very, very small. Still, many doctors feel that any woman with adenosis should have very careful screening and follow-up.
HPV is short for human papillomavirus. HPVs are a large group of related viruses. Each virus in the group is given a number, which is called an HPV type.
Certain HPV types have been linked with cancers of the cervix and vulva in women, cancer of the penis in men, and cancers of the anus and throat (in men and women). They've also been linked to VAIN, and HPV is found in most cases of vaginal cancer. These types are known as high-risk types of HPV and include HPV 16 and HPV 18, as well as others. Infection with a high-risk HPV may produce no visible signs until pre-cancerous changes or cancer develops.
Vaccines have been developed to help prevent infection with some types of HPV. See HPV for more information.
Having cervical cancer or pre-cancer (cervical intraepithelial neoplasia or cervical dysplasia) increases a woman’s risk of vaginal squamous cell cancer. This is most likely because cervical and vaginal cancers have much the same risk factors, such as HPV infection and smoking.
Some studies suggest that treating cervical cancer with radiation therapy may increase the risk of vaginal cancer, but this was not seen in other studies, and the issue remains unresolved.
Smoking cigarettes more than doubles a woman’s risk of getting vaginal cancer.
Drinking alcohol might affect the risk of vaginal cancer. A study of alcoholic women found more cases of vaginal cancer than expected. But this study was flawed because it didn’t look at other factors that can alter risk, such as smoking and HPV infection. A more recent study that did take these other risk factors into account found a decreased risk of vaginal cancer in women who do not drink alcohol at all.
Infection with HIV (human immunodeficiency virus), the virus that causes AIDS, increases the risk of vaginal cancer.
In some women, stretched pelvic ligaments may let the uterus sag into the vagina or even extend outside the vagina. This is called uterine prolapse. It can be treated with surgery or by wearing a pessary, a device to keep the uterus in place. Some studies suggest that long-term (chronic) irritation of the vagina in women using a pessary may slightly increase the risk of squamous cell vaginal cancer. But this is very rare, and no studies have clearly proven that pessaries cause vaginal cancer.
Our team is made up of doctors and oncology certified nurses with deep knowledge of cancer care as well as journalists, editors, and translators with extensive experience in medical writing.
Huo D, Anderson D, Palmer JR, Herbst AL. Incidence rates and risks of diethylstilbestrol-related clear-cell adenocarcinoma of the vagina and cervix: Update after 40-year follow-up. Gynecol Oncol. 2017;146(3):566-571.
National Cancer Institute. SEER. Vagina Cancer SEER Incidence Rates by Age at Diagnosis, 2010-2014 By Race/Ethnicity. Accessed at https://seer.cancer.gov/explorer/application.php?site=62&data_type=1&stat_type=3&hdn_sex=3&chk_race_1=1&chk_race_5=5&chk_race_4=4&chk_race_3=3&chk_race_6=6&chk_race_2=2&advopt_precision=1 on March 6, 2018.
National Cancer Institute. Vaginal Cancer Treatment (PDQ®)–Patient Version. October 13, 2017. Accessed at www.cancer.gov/types/vaginal/patient/vaginal-treatment-pdq on March 6, 2018.
Saito T, Tabata T, Ikushima H, et al. Japan Society of Gynecologic Oncology guidelines 2015 for the treatment of vulvar cancer and vaginal cancer. Int J Clin Oncol. 2017 Nov 20.
Sinno A.K. Human papillomavirus genotype prevalence in invasive vaginal cancer from a registry-based population. Obstet. Gynecol. 2014;123(4):817-821.
Society of Gynecologic Oncology. Vaginal Cancer Risk Factors. Accessed at www.sgo.org/patients-caregivers-survivors/caregivers/vaginal-cancer-risk-factors/ on March 6, 2018.
Last Revised: March 19, 2018